Biomedical translational research is aimed at meeting the unmet clinical needs that ultimately affect some measure of patient care and quality of life. Case Western Reserve University (CWRU) has engaged with the Wallace H. Coulter Foundation (WHCF) to change how biomedical translational research is conducted. In 2006, a partnership began between CWRU and WHCF and resulted in a joint $20 million endowment to run the program in perpetuity. This partnership has the Coulter Process at its core. This multi-step process fully integrated and executed has been proven to help mitigate risks and increase the odds of commercialization for the projects that go through the process. Additionally, projects subjected to the Coulter process have been very successful raising follow-on funding to include non-dilutive funding such as SBIR/STTR as well as equity funding such as Angel and VC. Affinity Therapeutics is one example of CWRU’s many success stories.